参考文献
[1]Berg PA, Klein R.Antimitochondrial antibody in primary biliary cirrhosis and other disorders: def inition and clinical relevance[J].Digestive Diseases, 1992, 10(2): 85—101.
[2]Bowlus CL, Gershwin ME.The diagnosis of primary biliary cirrhosis[J].Autoimmunity reviews, 2014, 13(4—5): 441—444.
[3]Shuai Z, Wang J, Badamagunta M, et al.The f ingerprint of antimitochondrial antibody and the etiology of primary biliary cholangitis[J].Hepatology, 2017, 65(5): 1670—1682.
[4]Marshall M, Kaplan MD, M Eric Gershwin MD.Primary Biliary Cirrhosis.[J].New England Journal of Medicine.2005, 353(12): 1261—1273.
[5]Tana MM, Shums Z, Milo J, et al.The signif icance of autoantibody changes over time in primary biliary cirrhosis[J].American journal of clinical pathology, 2015, 144(4): 601—606.
[6]Invernizzi P, Crosignani A, Battezzati PM, et al.Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and-negative primary biliary cirrhosis[J].Hepatology, 1997, 25(5): 1090—1095.
[7]Berg PA, Klein R.Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9[J].Klinische Wochenschrift, 1986, 64(19): 897—909.
[8]Zheng B, Vincent C, Fritzler MJ, et al.Prevalence of systemic sclerosis in primary biliary cholangitis using the new ACR/EULAR classif ication criteria[J].The Journal of rheumatology, 2017, 44(1): 33—39.
[9]Tomizawa M, Shinozaki F, Fugo K, et al.Anti-mitochondrial M2 antibody-positive autoimmune hepatitis[J].Experimental and Therapeutic Medicine, 2015, 10(4): 1419—1422.
[10]Konishi H, Fukuzawa K, Mori S, et al.Anti-mitochondrial M2 antibody enhance the risk of supraventricular arrhythmias in patients with elevated hepatobiliary enzyme levels[J].Internal Medicine, 2017, 56(14): 1771—1779.
[11]张洋，李永哲，冯雪，等.抗线粒体抗体M2亚型抗体三种检测方法的比较及其对原发性胆汁性肝硬化的诊断价值研究[J].中国实验诊断学，2008，12（9）：1073—1075.
[12]Calise SJ, Zheng B, Hasegawa T, et al.Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies[J].Clinical Chemistry and Laboratory Medicine (CCLM), 2018, 56(10): 1789—1798.
[13]Nozawa K, Fritzler MJ, Chan EK.Unique and shared features of Golgi complex autoantigens[J].Autoimmunity Reviews, 2005, 4(1): 35—41.
[14]Wallis D, Greig A, Dunphy J, et al.Anti-Golgi autoantibodies: prevalence and disease associations in a rheumatic disease population[J].International journal of rheumatic diseases, 2012, 15(2): e23—e25.
[15]Ma L, Zeng A, Chen Y, et al.Anti-golgi antibody: Prevalence and disease association in Chinese population[J].Clinica Chimica Acta, 2019,496: 121—124.
[16]Vermeersch P, Van den Bergh K, Blockmans D, et al.Anti-Golgi autoantibodies are not clinically associated with systemic autoimmune diseases[J].Annals of the rheumatic diseases, 2011, 70(1): 234—235.
[17]Nozawa K, Fritzler MJ, von Mühlen CA, et al.Giantin is the major Golgi autoantigen in human anti-Golgi complex sera[J].Arthritis Res Ther,2003, 6(2): R95—102.
[18]Carcamo WC, Satoh M, Kasahara H, et al.Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells[J].PloS one, 2011, 6(12): e29690.
[19]Keppeke GD, Calise SJ, Chan EK, et al.Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy[J].World journal of gastroenterology, 2016, 22(6): 1966—1974.
[20]Climent J, Morandeira F, Castellote J, et al.Clinical correlates of the “rods and rings” antinuclear antibody pattern[J].Autoimmunity, 2016,49(2): 102—108.
[21]Keppeke GD, Nunes E, Ferraz ML, et al.Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α[J].PloS one, 2012, 7(9): e45392.